Fairvalue-Calculator Fairvalue-Calculator
EN DE

LENZ Therapeutics, Inc (LENZ) Fair Value & Analysis

Healthcare · US · Market cap $193M

Price$5.75
Fair Value$8.93
Upside+55.3%
Quality95/100
Evidence: Low Range $5.89 – $11.16

Fair value as of: Jun 25, 2026

Analysis

LENZ Therapeutics, Inc (LENZ) currently trades at $5.75, while our model-based Fair Value estimate is $8.93 — implying the stock looks roughly 55.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is LENZ Therapeutics, Inc (LENZ) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $8.93 versus a price of $5.75 — about +55% (undervalued). Model-based estimate, not financial advice.
What is the fair value of LENZ?
Our 21-model fair value for LENZ Therapeutics, Inc is $8.93 (as of Jun 25, 2026), built from audited fundamentals. The current price is $5.75.
What is the quality score of LENZ?
LENZ Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.